Interaction Checker

Prescribing Resources

We have produced various materials in PDF format to aid the use of experimental agents in the treatment of COVID-19.

These resources are freely available and the Liverpool Drug Interactions Group would like to encourage the dissemination (with an appropriate acknowledgement) of this drug-drug interaction information for non-commercial use. If referencing these Prescribing Resources, it is important to include the publication date since these resources are updated as new data come to light. Please cite as: [Prescribing Resource Title], [PDF Publication Date], University of Liverpool, available from www.covid19-druginteractions.org, [accession date].

Detailed recommendations for interactions with experimental COVID-19 antiviral therapies.

UPDATED – COVID-19 treatments split into antiviral and immune based therapies. Azithromycin and nitazoxanide added to these COVID-19 antiviral therapies.

Details of the nature of drug interactions with experimental COVID-19 therapies and many comedication classes are given in this PDF.

Click here to view PDF.

Updated 04 June 2020

Detailed recommendations for interactions with experimental COVID-19 immune therapies.

UPDATED – COVID-19 treatments split into antiviral and immune based therapies. Anakinra and sarilumab added to these COVID-19 antiviral therapies.

Details of the nature of drug interactions with experimental COVID-19 therapies and many comedication classes are given in this PDF.

Click here to view PDF.

Updated 04 June 2020

At-a-glance summary of interactions with experimental COVID-19 antiviral therapies.

UPDATED – COVID-19 treatments split into antiviral and immune based therapies. Azithromycin and nitazoxanide added to these COVID-19 antiviral therapies

A summary of interactions with experimental COVID-19 antiviral therapies and over 500 comedications are given in this PDF.

Click here to view PDF.

Updated 27 May 2020

At-a-glance summary of interactions with experimental COVID-19 immune therapies.

UPDATED – COVID-19 treatments split into antiviral and immune based therapies. Anakinra and sarilumab added to the COVID-19 immune therapies

A summary of interactions with experimental COVID-19 immune therapies and over 500 comedications are given in this PDF.

Click here to view PDF.

Updated 27 May 2020

Administration in cases of swallowing difficulties.

UPDATED - anakinra, azithromycin, nitazoxanide and sarilumab added.

Advice for administering experimental COVID-19 therapies to patients who cannot swallow is given in this PDF.

Click here to view PDF.

Updated 28 May 2020

Evaluating the interaction risk of experimental COVID-19 therapies.

UPDATED - information added for anakinra, azithromycin, nitazoxanide and sarilumab.

This document explains how we have evaluated the drug-drug interaction risk of the experimental COVID-19 therapies and gives details of their metabolism, interaction potential and cardiac effects.

Click here to view PDF.

Updated 28 May 2020

Academic Sponsors / Collaborators
Editorial Sponsors